rosuvastatine mylan 10 mg filmtablette
mylan - rosuvastatin calcium - filmtablette - 10 mg - rosuvastatin calcium 10.4 mg - rosuvastatin
rosuvastatine mylan 5 mg filmtablette
mylan - rosuvastatin calcium - filmtablette - 5 mg - rosuvastatin calcium 5.198 mg - rosuvastatin
rosuvastatine mylan 20 mg filmtablette
mylan - rosuvastatin calcium - filmtablette - 20 mg - rosuvastatin calcium 20.792 mg - rosuvastatin
rosuvastatine mylan 40 mg filmtablette
mylan - rosuvastatin calcium - filmtablette - 40 mg - rosuvastatin calcium 41.584 mg - rosuvastatin
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rosuvastatin viatris 5 mg filmtabletten
mylan pharma gmbh - rosuvastatinum - filmtabletten - rosuvastatinum 5 mg ut rosuvastatinum calcicum, lactosum monohydricum 47.696 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.9 µg, e 104, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 3 µg. - reduktion der serumcholesterinkonzentration. vorbeugung kardiovaskulärer ereignisse bei erwachsenen mit normalem ldl-cholesterin spiegel und erhöhtem risiko von atherosklerotischen kardiovaskulären erkrankungen. - synthetika
rosuvastatin viatris 10 mg filmtabletten
mylan pharma gmbh - rosuvastatinum - filmtabletten - rosuvastatinum 10 mg ut rosuvastatinum calcicum, lactosum monohydricum 42.489 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 2.6 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 3 µg. - reduktion der serumcholesterinkonzentration. vorbeugung kardiovaskulärer ereignisse bei erwachsenen mit normalem ldl-cholesterin spiegel und erhöhtem risiko von atherosklerotischen kardiovaskulären erkrankungen. - synthetika
rosuvastatin viatris 20 mg filmtabletten
mylan pharma gmbh - rosuvastatinum - filmtabletten - rosuvastatinum 20 mg ut rosuvastatinum calcicum, lactosum monohydricum 84.978 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.1 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 6 µg. - reduktion der serumcholesterinkonzentration. vorbeugung kardiovaskulärer ereignisse bei erwachsenen mit normalem ldl-cholesterin spiegel und erhöhtem risiko von atherosklerotischen kardiovaskulären erkrankungen. - synthetika
rosuvastatin viatris 40 mg filmtabletten
mylan pharma gmbh - rosuvastatinum - filmtabletten - rosuvastatinum 40 mg ut rosuvastatinum calcicum, lactosum monohydricum 64.150 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.1 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 6 µg. - reduktion der serumcholesterinkonzentration. vorbeugung kardiovaskulärer ereignisse bei erwachsenen mit normalem ldl-cholesterin spiegel und erhöhtem risiko von atherosklerotischen kardiovaskulären erkrankungen. - synthetika
ibuprofen adgc 400 mg filmtabletten
zentiva pharma gmbh (8075753) - ibuprofen - filmtablette - 400 mg - teil 1 - filmtablette; ibuprofen (05682) 400 milligramm